Q2 2019 Orion Oyj Earnings Call Transcript
(foreign language) Good afternoon. Welcome to Orion's Earnings Call First Half 2019. My name is Timo Lappalainen, I'm the President and CEO of the company.
I will firstly have a few prepared remarks. Thereafter, I will invite our CFO, Jari Karlson to join me here to the podium and we are happy to address any questions, comments that you may have.
At this stage, I want to draw your attention to the disclaimer. This presentation contains forward-looking statements, which involve risks and uncertainty factors and Orion assumes no obligation to update or revise any information included in this presentation.
So if we kick off by getting -- reviewing some highlights for the first half of 2019. Of course for the company, the major, major event was the submission of marketing authorization for darolutamide, our prostate cancer agent candidate in the main markets. And those include the U.S., Japan, Europe, and now the role -- the rolling submissions in many other markets are taking place. Also
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |